[
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It is therefore possible that studies in healthy volunteers could overestimate next-day impairment compared with studies in people with insomnia.Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "SDLP scores typically increase compared with placebo after ingestion of alcohol or hypnotic drugs, as illustrated in Figure 1 [21].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Results\nSearch results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The older studies tended to be unclear about some aspects, such as randomization and an absence of conflict of interest information, and a few studies excluded subjects who discontinued early (Table 1).Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).Premature termination of driving test\nResults for premature termination of the driving test are summarized in Table 2.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Search results\nThe PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The PRISMA flow diagram in Figure 2 summarizes the results of the literature searches and the screening/selection process.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Standard deviation of lateral position relative to placebo (ΔSDLP) analysis\nClinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Confidence intervals for individual studies may vary from those reported by study authors as they are based on z-statistic.Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Clinically significant differences in ΔSDLP, with the 95% confidence interval (CI) crossing +2.4 cm (equivalent to driving with a blood alcohol concentration of 0.05%), were shown in healthy volunteers after a single evening dose of zopiclone 7.5 mg in all (10/10) studies (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Of the three studies that also measured ΔSDLP after a second dose of zopiclone a week later (Day 9), the study of lemborexant [21] showed the same result at the second time point, whereas the two studies of suvorexant [34, 35] failed to demonstrate a clinically meaningful effect of zopiclone at the second time point as the 95% CI did not cross +2.4 cm (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows meta-analysis results for ΔSDLP for treatments other than zopiclone in single or multiple doses, including healthy volunteers and subjects with insomnia or prior use of hypnotics.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Flunitrazepam 2 mg was only studied in patients with insomnia and showed clinically meaningful changes in ΔSDLP in two out of three studies (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The other treatment studied in patients with insomnia, zolpidem IR, showed no clinically meaningful effect on ΔSDLP (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Lemborexant 5 mg or 10 mg showed no statistically or clinically significant difference from placebo in SDLP after a single dose, or after 8 days of treatment, in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Suvorexant also showed no clinically meaningful effect on ΔSDLP after a single dose or after 8 days of treatment in healthy volunteers, as was also the case for zaleplon and temazepam after a single dose (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Ramelteon was the only treatment that showed a clinically meaningful change in ΔSDLP after a single dose in healthy volunteers (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]